Licensed vaccine
Flublok Quadrivalent
FDA-licensed vaccine · Protein Sciences Corporation · STN 125285
Key facts
| Trade name | Flublok Quadrivalent |
|---|---|
| Proper name | Influenza Vaccine (Quadrivalent) |
| Manufacturer | Protein Sciences Corporation |
| Submission tracking number (STN) | 125285 |
| FDA product areas | Biologics |
| Recent FDA documents | June 30, 2023 Approval Letter - Flublok Quadrivalent, July 1, 2022 Approval Letter - Flublok Quadrivalent, May 11, 2022 Approval Letter - Flublok Quadrivalent, July 2, 2021 Approval Letter - Flublok, July 2, 2020 Approval Letter - Flublok, May 12, 2020 Approval Letter - Flublok, Clinical Review - Flublok Quadrivalent, Statistical Review - Flublok Quadrivalent, July 2, 2019 Approval Letter - Flublok, Package Insert - Flublok Quadrivalent, April 15, 2019 Approval Letter - Flublok Quadrivalent, June 29, 2018 Approval Letter - Flublok Quadrivalent |
| FDA page updated | Jul 3, 2023 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: